Bryxta 300 mg Injection
  1. Home
  2. Pharma Products
  3. Cadila Healthcare Ltd
  4. Bryxta 300 mg Injection

Bryxta 300 mg Injection

Bryxta 300 mg Injection contains bevacizumab, a monoclonal antibody used in the treatment of several types of cancer. It is supplied as 300 mg/12 mL concentrate for solution for infusion and is administered by a healthcare professional. Bevacizumab blocks VEGF and helps inhibit the formation of new blood vessels that support tumor growth.

BUY NOW

Category

Bryxta 300 mg Injection may be used in treatment regimens for metastatic colorectal cancer, non-squamous non-small cell lung cancer, kidney cancer, cervical cancer, and certain ovarian, fallopian tube, and primary peritoneal cancers. Its active ingredient, bevacizumab, binds to vascular endothelial growth factor and reduces tumor-associated blood-vessel formation. The medicine is given as a slow intravenous infusion under specialist supervision and should not be administered as an IV push or bolus. Patients require appropriate monitoring for blood pressure changes, bleeding, infusion reactions, wound-healing problems, and other treatment-related effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 300 mg
Concentration 25 mg/mL
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Pack Size 1 Vial, 12 mL

Product Also Known As

Bryxta 300 mg Injection, Bryxta 300 Injection, Bevacizumab 300 mg Injection, Bevacizumab 300 mg/12 mL Injection, Bryxta Bevacizumab Injection, Anti-VEGF Cancer Injection